timothy_wright_teva

Teva hires new business development head

pharmafile | March 25, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, timothy wright 

Teva Pharmaceutical Industries has confirmed the appointment of Timothy Wright to its executive leadership team to head up business development, strategy and innovation.

In this new role which begins in April, Wright will be responsible for identifying new sources of growth for the firm and will report directly to its president and chief executive Erez Vigodman.

Wright has almost 30 years of experience in pharma and biotech with a career that has included roles comprising chief executive, head of business development and strategy and head of global operations, and has worked in partnerships with academia.

Advertisement

Most recently, he was the director of the Drug Discovery and Development Institute at The Ohio State University Comprehensive Cancer Center. Wright has also served previously as president of Covidien Pharmaceuticals from 2007-2010, and held senior roles at AAI Pharmaceuticals/Xanodyne and Elan Pharmaceuticals.

“The addition of Tim to our leadership team complements the strong management capabilities we have in Teva. He has a wealth of global experience which will serve us well as we look to create a new and exciting future for Teva,” says Vigodman. “Tim is known for leading the transformation of large companies.”

“I am excited to join Teva at such a transformative time for both the company and industry in general,” adds Wright.

Related Content

Teva announces positive results from trial of AJOVY for migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

judge-gavel-1461966002dbr

Teva’s cancer drug Bendeka protected from generics until 2031, judge rules

A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe …

The Gateway to Local Adoption Series

Latest content